Anish Thomas, MD
Interventional Cardiology · Saint Louis, MONPI 1912096231
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Johnson & Johnson at 29.9% of the total. Reporting peaked in 2021 at $29,734 and has fallen 65.6% since, to $10,242 in 2025. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 765 payments — averaging $222.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$51K
- Abbott$40K
- Terumo Medical Corporation$13K
- Shockwave Medical, Inc$12K
- Edwards Lifesciences$11K
- Bard Peripheral Vascular, Inc.$10K
- plus $33K from 31 others
Across 41 payments — averaging $30,848 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$1M
- Medtronic$195K
- M.a. Med Alliance S.A.$31K
Across 3 payments — averaging $16,667 each. An ownership or investment interest held by the physician or an immediate family member.
- Vasorum USA Inc.$50K
What the payments were for
- Consulting fees$29,87918%
- Speaking & faculty fees$97,99357%
- Travel & lodging$16,54710%
- Food & beverage$25,94315%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 66 | $51,015 |
| Abbott | 123 | $40,452 |
| Terumo Medical Corporation | 23 | $13,246 |
| Shockwave Medical, Inc | 75 | $11,526 |
| Edwards Lifesciences | 270 | $11,295 |
| Bard Peripheral Vascular, Inc. | 11 | $9,910 |
| Philips North America LLC | 46 | $8,518 |
| Medtronic(2 entities) | 37 | $8,458 |
| Cardiovascular Systems Inc. | 14 | $6,658 |
| Penumbra, Inc. | 6 | $2,855 |
| Abiomed | 17 | $1,707 |
| Inspiremd Ltd | 4 | $1,186 |
| Surmodics, Inc. | 1 | $750 |
| Boston Scientific | 15 | $720 |
| Endologix LLC | 4 | $530 |
| Cordis US CORP. | 4 | $332 |
| Novartis | 10 | $193 |
| Vasorum USA Inc. | 1 | $167 |
| Intact Vascular, Inc. | 1 | $146 |
| Reflow Medical Inc | 2 | $105 |
| Pfizer | 7 | $103 |
| Cardiva Medical, Inc. | 2 | $88 |
| Amgen | 6 | $85 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Recor Medical Inc | 1 | $57 |
| Angiodynamics, Inc. | 1 | $55 |
| Janssen Scientific Affairs, LLC | 1 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $48 |
| Biosense Webster, Inc. | 2 | $34 |
| Merck | 2 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| CSL Behring | 1 | $21 |
| AstraZeneca | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$50,000
- Omnilink Elite vascular stent system$20,383
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$10,928
- Navicross$8,175
- Diamondback Peripheral$6,557
- Abre$5,409
- GlideWire$4,678
- Supera peripheral stent system$4,558
- XIENCE SIERRA$4,000
- R2P MISAGO$3,825
- TR Band$3,825
- METACROSS OTW$3,825
- ABSOLUTE PRO$3,650
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,406
- Spectranetics Undiv$3,200
- Benchmark$2,400
- Xience V coronary stent system$2,188
- (9520) IGT Devices Undivided$1,748
- SAPIEN 3 Ultra RESILIA$1,575
- GLIDESHEATH SLENDER$1,350
How this compares
$170,515 in reported general payments places this provider in the 95th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 216 | $231,082 |
| EliquisApixaban | 192 | $200,304 |
| EntrestoSacubitril/Valsartan | 134 | $139,329 |
| JardianceEmpagliflozin | 83 | $92,574 |
| Repatha SureclickEvolocumab | 56 | $64,676 |
| Prasugrel Hcl | 54 | $5,937 |
| ClopidogrelClopidogrel Bisulfate | 462 | $5,433 |
| Atorvastatin Calcium | 474 | $5,214 |
| Metoprolol Succinate | 347 | $3,272 |
| Cilostazol | 92 | $2,367 |
| Rosuvastatin Calcium | 176 | $2,365 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 156 | $2,114 |
| Ezetimibe | 69 | $1,701 |
| Amlodipine Besylate | 242 | $1,688 |
| Carvedilol | 156 | $1,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $51,015 | $231,082216 claims |
| PfizerEliquis | $103 | $200,304192 claims |
| NovartisEntresto | $193 | $139,329134 claims |
| Boehringer IngelheimJardiance | $15 | $92,57483 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Saint Louis
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Alan ZajariasSaint Louis$203K
- Gus TheodosSaint Louis$165K
- Prashanth ThakkerSaint Louis$129K
- Marc SintekSaint Louis$119K
- George KichuraSaint Louis$118K
- Gil VardiSaint Louis$106K
- Anthony SonnSaint Louis$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.